Micropharma Limited

Company From basic research to product development Micropharma is focused on innovation. We apply a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases. What we do Micropharma Limited discovers and develops bacteria as biotherapeutics for metabolic diseases. The Company uses its proprietary discovery and development platform ProSelect to screen and select bacteria capable of expressing phenotypic traits that can effectively target metabolic pathways recognized as having therapeutic potential. Micropharma then uses its novel fermentation and optimization techniques to induce over-expression of these traits. The Company has proven the effectiveness of ProSelect by successfully developing Cardioviva™, the world's first disease-specific, biomarker-linked, and therapeutic bacteria product. Cardioviva™ is a highly bile-salt-hydrolase (BSH) active bacteria which proved safe and effective at lowering LDL-C in two large double-blind, placebo-controlled, randomized, multicenter trial.